168 results on '"Modell S"'
Search Results
2. Quantifizierung des Amyloid-Vorläuferproteins im Liquor von Patienten mit einer Demenz vom Alzheimer Typ
3. Development of a state system for optimal health as a cornerstone for individuals with intellectual disabilities
4. Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism
5. Variants within the GABA transaminase (ABAT) gene region are associated with somatosensory evoked EEG potentials in families at high risk for affective disorders
6. List of Contributors, Part 2
7. Efficacy and tolerability of ready-to-use intravenous paracetamol solution as monotherapy or as an adjunct analgesic therapy for postoperative pain in patients undergoing elective ambulatory surgery: open, prospective study
8. The Munich vulnerability study on affective disorders: premorbid neuroendocrine profile of affected high-risk probands
9. Impaired divided attention predicts delayed response and risk to relapse in subjects with depressive disorders
10. The Munich vulnerability study on affective disorders: premorbid psychometric profile of affected individuals
11. The 'performativity thesis' and its critics: towards a relational ontology of management accounting
12. The 'performativity thesis' and its critics: towards a relational ontology of management accounting
13. Fragmented utopias
14. Primary Immune Deficiency Treatment Consortium (PIDTC) report
15. Variants within the GABA transaminase (ABAT) gene region are associated with somatosensory evoked EEG potentials in families at high risk for affective disorders
16. Children with disabilities: victimization, sexuality and communication
17. Polymorphisms within the 4-aminobutyrate aminotransferase gene are associated with long-latency somatosensory potentials in families vulnerable for affective disorders
18. Psychosocial Functioning in Patients with Schizophrenia Treated with Aripiprazole – an Office-based Real-world Setting. Results from the German Post-marketing Surveillance Study
19. Switching to Aripiprazole in Outpatients with Schizophrenia Experiencing Insufficient Efficacy and/or Safety/Tolerability Issues with Risperidone: A Randomized, Multicentre, Open-label Study
20. Genetic determinants of neurobiological vulnerability markers in depression
21. Intramuscular Aripiprazole for the Treatment of Acute Agitation Associated with Schizophrenia: Sub-analysis of a Double-blind, Controlled, Dose-ranging Study
22. Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
23. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, placebo- and lithium-controlled study
24. Office-based post-marketing surveillance study on the influence of long term therapy with aripiprazole in patients with schizophrenia
25. Postmarketing surveillance of aripiprazole in a hospital-based setting
26. Metabolic Syndrome in Patients Enrolled in a Clinical Trial of Aripiprazole in the Maintenance Treatment of Bipolar Disorder
27. Aripiprazole: Pharmacodynamics of a Dopamine Partial Agonist for the Treatment of Schizophrenia
28. Effects of long-term (up to 5 years) open-label treatment with aripiprazole
29. Efficacy and safety of lower doses of aripiprazole
30. Aripiprazole reduces agitation without excessive sedation
31. Change in HPA system function predicts treatment response in depression
32. Long-term efficacy and safety of aripiprazole vs. olanzapine in schizophrenia: a 52-week, open-label extension study
33. Individual symptom analysis in pivotal aripiprazole schizophrenia trials
34. S.3.2 Endophenotypes for affective disorders
35. P.2.076 Efficacy of aripiprazole and perphenazine in severe schizophrenia resistant to treatment with atypical antipsychotics
36. Efficacy and tolerability of aripiprazole compared to perphenazine in treatment-resistant schizophrenia
37. Subsyndromal AMDP scales to distinguish pathogenetically homogenous subgroups of affective disorders
38. Neuropsychological deficits and long-term outcomes in patients with affective disorders
39. Munich Vulnerability Study – Familial vulnerability for affective disorders: Search for endophenotypes
40. Prediction of response to antidepressant monotherapy
41. The effects of RS-86 on sleep with respect to depression and HLA-type
42. Efficacy of aripiprazole in the treatment of mania
43. HPA axis dysregulation and suicidal behavior in depression – Differentiation of a genetically distinct subgroup?
44. Long-term treatment with aripiprazole and its effects on negative and affective symptoms of schizophrenia
45. Is there a genetic continuum between anxiety and depression?
46. Die Parkinson’s Disease Sleep Scale (PDSS)
47. Pharmacological and Nonpharmacological Factors Influencing Hypothalamic–Pituitary–Adrenocortical Axis Reactivity in Acutely Depressed Psychiatric In-patients, Measured by the Dex-CRH Test
48. The Munich Vulnerability Study on Affective Disorders: risk factors for unipolarity versus bipolarity
49. Involuntary Vocalisations and a Complex Hyperkinetic Movement Disorder Following Left Side Thalamic Haemorrhage
50. Polysomnographic, neuroendocrine and psychometric risk factors for depression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.